entertainment -WSS

entertainment

author：comprehensive 2025-08-24 19:12:24 - browse：15

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Astellas still sees hope in its gene therapy after four deaths

focus

WSS

NYU radiologists take on the challenge of expensive MRI machines

Ambulance rides for just $100? Advisers want major billing fixes

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Morphosys mixed study results for blood cancer drug

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Why medical students are struggling with mental health

knowledge

entertainment

focus

Drug repurposing or repositioning? The language matters

Astellas still sees hope in its gene therapy after four deaths

Medical leaders decry Supreme Court decision on affirmative action

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Virginia high school admissions case could be legal follow

STAT Executive Editor Rick Berke on STAT's 8th birthday

Moonlake's readout produced a cash windfall. Risks remain

Ransomware attacks on hospitals: Study outlines patient impact

Jerome Adams on the need for new antivirals for Covid

Victims of gun violence feel impacts long after bullet wound

hotspot

White House calls on federal agencies to crack down on AI abuses

Ransomware attacks on hospitals: Study outlines patient impact

NYU radiologists take on the challenge of expensive MRI machines

Study: New antibiotic targets gonorrhea as well as last existing drug

FDA approves potent Eli Lilly obesity drug, Zepbound

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

focus

focus

Wikipedia

hotspot